Five Prime (FPRX)

Company Description

Five Prime is a leader in the discovery of innovative protein therapeutics.

We have developed a library of more than 5,700 human extracellular proteins, which we believe represent substantially all of the body’s medically important targets for protein therapeutics.

Building on this expertise in protein science, we have developed proprietary high-throughput protein screening technologies that we use to identify new targets for protein therapeutics in relatively short periods of time. As a result, we have built a pipeline of novel product candidates for cancer and inflammatory diseases.

Our drug discovery platform has also made us a sought-after discovery and development partner. To date we have generated over $262 million from collaborations with partners, including Bristol-Myers Squibb, GlaxoSmithKline and UCB Pharma.

Our strategy is to be opportunistic in our development programs. Pursuing clinical development of our product candidates both independently and in collaborations allows us to enhance the capital resources needed to strengthen our core technology and expand our product pipeline.

 

COMPANY ADDRESS
Two Corporate Drive
South San Francisco, CA 94080
United States

COMPANY PHONE
415-365-5600

COMPANY WEBSITE


Get BioInvest's perspective on Five Prime’s CEO

Latest Company News

Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior ... GlobeNewswire (press release) - Aug 17, 2017 SOUTH SAN FRANCISCO, Calif., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today ... Institutional Investors Lead Shift in Five Prime Therapeutics Inc (NASDAQ:FPRX ... - BZ Weekly Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Position Raised by Tudor ... - Markets Daily [...]
Thu, Aug 17, 2017 8:03:00 PM, Continue reading at the source
Five Prime Therapeutics' (FPRX) CEO Rusty Williams on Q2 2017 Results ... Seeking Alpha - Aug 9, 2017 Good day, ladies and gentlemen and welcome to the Five Prime Therapeutics, Inc. Second Quarter 2017 Earnings Call. As a reminder, this conference call maybe recorded. Five Prime Announces Second Quarter 2017 Results and Provides Business Update - GlobeNewswire (press release) Five Prime Therapeutics Inc. (FPRX) Settles Into New 52-Week Low on August 11 ... - Equities.com [...]
Wed, Aug 09, 2017 4:52:00 AM, Continue reading at the source
Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety ... GlobeNewswire (press release) - Jul 17, 2017 SOUTH SAN FRANCISCO, Calif., July 17, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today ... [...]
Mon, Jul 17, 2017 8:03:00 PM, Continue reading at the source
Five Prime Therapeutics founder, CEO to step down MarketWatch - Jun 21, 2017 Biotech company Five Prime Therapeutics, Inc. FPRX, +2.70% said late Wednesday founder and Chief Executive Lewis T. "Rusty" Williams plans leave his post and become executive chairman of the board by next year. [...]
Wed, Jun 21, 2017 8:33:00 PM, Continue reading at the source
Five Prime Therapeutics updates on FPA144 results Seeking Alpha - Jun 3, 2017 ... Five Prime Chief Medical Officer Helen Collins. "While we have seen encouraging monotherapy activity as a late-line treatment, we believe front-line chemotherapy combination therapy will provide the greatest patient benefit," she adds. [...]
Sat, Jun 03, 2017 8:26:00 PM, Continue reading at the source
Five Prime Welcomes Garry Nicholson to Board of Directors GlobeNewswire (press release) - May 15, 2017 SOUTH SAN FRANCISCO, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today ... [...]
Mon, May 15, 2017 8:03:00 PM, Continue reading at the source
Five Prime Therapeutics At An Attractive Entry Level Seeking Alpha - May 12, 2017 Five Prime Therapeutics (NASDAQ:FPRX) has suffered a rather dramatic decline in share price from its high of $60.98 in mid-November to its current levels in the high $20s. [...]
Fri, May 12, 2017 10:52:00 PM, Continue reading at the source
Five Prime Therapeutics' (FPRX) CEO Rusty Williams on Q1 2017 Results ... Seeking Alpha - May 5, 2017 Good day, ladies and gentlemen and welcome to the Five Prime Therapeutics, Inc. First Quarter 2017 Earnings Call. As a reminder, this conference maybe recorded. [...]
Fri, May 05, 2017 4:30:00 AM, Continue reading at the source
Five Prime Therapeutics: Initiating Coverage With A Buy Rating And A $56 Price ... Seeking Alpha - Mar 31, 2017 Five Prime Therapeutics (FPRPX) is a San Francisco-based immune-oncology company that is developing novel monoclonal antibodies for the treatment of various cancers. [...]
Fri, Mar 31, 2017 1:13:00 AM, Continue reading at the source
Five Prime At Lows With Looming Catalysts Seeking Alpha - Mar 27, 2017 Company has a diversified pipeline with several promising clinical candidates, a validating partnership with Bristol-Myers Squibb, and a large cash position. [...]
Mon, Mar 27, 2017 4:18:00 PM, Continue reading at the source